Hyoscyamine

PreclinicalSmall molecule

UUniversity of Kansas Medical Center

Hyoscyamine is one of 42 small molecule programs targeting Children. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ChildrenCompleted

ChildrenPreclinical

Completed

Competition

Competitive Landscape

58 competitors in Children

#DrugCompanyPhaseTrials

Promacta

GSK

Approved

2 2

Ozempic

Novo Nordisk

Approved

1 3

Gleevec

Novartis

Approved

1 4

Oncaspar

SServier

Approved

2 5

Velcade

SShilpa Grover, MD, MPH

Approved

1 6

Sprycel

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Approved

1 7

Byetta

AstraZeneca

Phase 3

1 8

Neurontin

VViatris Specialty LLC

Phase 3

2 9

Somavaratan

Novo Nordisk

Phase 3

1 10

Veklury

Gilead

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Irritation1 trial

Use of Hyoscyamine Versus Tamsulosin for Management of Ureteral Stent Irritation

Terminated·UUniversity of Kansas Medical Center·Phase 4·NCT03750656·5 enrolled

Children1 trial

Efficacy of Open Label Placebo in Children With FGIDs

Completed·—·N/A·NCT02389998·31 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Hyoscyamine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Hyoscyamine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Hyoscyamine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Kansas Medical Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: UUniversity of Kansas Medical Center

Hyoscyamine

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Irritation1 trial

Children1 trial

References

Drug Info

Quick Facts

Related News